{"id":755,"date":"2026-09-01T16:45:45","date_gmt":"2026-09-01T16:45:45","guid":{"rendered":"https:\/\/nhdbio.com\/resources\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/"},"modified":"2026-09-01T16:45:45","modified_gmt":"2026-09-01T16:45:45","slug":"phase-3-studien-zu-bremelanotid-reconnect-und-fda-zulassungshinweise","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/de\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/","title":{"rendered":"Bremelanotid RECONNECT-Studien: Endpunkte, Sicherheit und FDA-Umfang"},"content":{"rendered":"

Bremelanotid hat eine echte FDA-zugelassene Erfolgsbilanz als Fertigarzneimittel, sein Anwendungsbereich ist jedoch begrenzt. Die RECONNECT-Studien untersuchten pr\u00e4menopausale Frauen mit erworbenem, generalisiertem HSDD \u2013 nicht M\u00e4nner, Leistungssteigerung oder ein generisches PT-141-Forschungsmaterial.<\/p>

Beweise auf einen Blick<\/h2>
  • In den beiden Phasen der 3-Studien wurden 1,267-Frauen randomisiert; 1,202 geh\u00f6rten zur Wirksamkeitspopulation.<\/li>
  • Ver\u00e4nderungen zwischen den Gruppen beg\u00fcnstigten Bremelanotid f\u00fcr die Endpunkte \u201eBegehren\u201c und \u201eBelastung\u201c, ein Post-hoc-Messwert f\u00fcr ein befriedigendes Ereignis unterschied sich jedoch nicht signifikant.<\/li>
  • \u00dcbelkeit, Hitzewallungen und Kopfschmerzen traten zumindest bei 10% auf und waren h\u00e4ufiger als unter Placebo.<\/li><\/ul><\/div><\/div>
    \"Visualisierung
    Originale redaktionelle Forschungsillustration. Es handelt sich nicht um eine Studienfigur, ein Patientenbild, ein Produktfoto, ein geliefertes Testergebnis oder eine Darstellung einer Katalogcharge.<\/figcaption><\/figure>

    Studienprotokoll<\/h2>

    Die co-prim\u00e4ren Endpunkte waren Ver\u00e4nderungen im FSFI-Wunschdom\u00e4nen-Score und ein Distress-Item aus dem FSDS-DAO. Studienspezifische Wunschunterschiede waren 0.30 und 0.42; Die Belastungsunterschiede betrugen \u22120.37 und \u22120.29. Die statistische Signifikanz allein beschreibt nicht die Gr\u00f6\u00dfe oder Relevanz des Nutzens f\u00fcr jeden Einzelnen.<\/p>

    Design<\/strong>Zwei identische randomisierte, doppelblinde, placebokontrollierte 3-Phasenstudien<\/span><\/div>
    Randomisiert<\/strong>1,267 pr\u00e4menopausale Frauen<\/span><\/div>
    Integrierter Wunschunterschied<\/strong>0.35 versus Placebo; P<0.001<\/span><\/div>
    Integrierter Notunterschied<\/strong>\u22120.33 versus Placebo; P<0.001<\/span><\/div>
    Beschriftungsgrenze<\/strong>Nicht angezeigt f\u00fcr postmenopausale Frauen, M\u00e4nner, Kinder oder zur Leistungssteigerung<\/span><\/div><\/div><\/div>

    Ergebnisse im Kontext<\/h2>

    Die Arbeit berichtet \u00fcber keinen signifikanten Gruppenunterschied im Prozentsatz befriedigender sexueller Ereignisse in einer Post-hoc-Analyse. Durch die Beibehaltung dieses Null-Ergebnisses bleibt der Datensatz informativer als eine Zusammenfassung, die sich nur auf die Vorteile beschr\u00e4nkt.<\/p>

    Die aktuelle DailyMed-Kennzeichnung identifiziert Vyleesi als Bremelanotid-Injektion unter NDA 210557 und listet vor\u00fcbergehenden Blutdruckanstieg, Herzfrequenzabfall, \u00dcbelkeit und fokale Hyperpigmentierung als wichtige Sicherheitsinformationen auf. Dieses Etikett geh\u00f6rt zur genehmigten Formulierung und nicht zu einem Forschungskatalogelement.<\/p>

    Was die Beweise nicht belegen k\u00f6nnen<\/h2>

    Die Evidenzpopulation und die Indikation sind spezifisch; Weitergehende Behauptungen zur sexuellen Leistungsf\u00e4higkeit werden nicht unterst\u00fctzt.<\/p>

    Die entscheidenden Studien wurden von der Industrie finanziert.<\/p>

    Eine zugelassene aktive Einheit macht ein unabh\u00e4ngig beschafftes Material nicht zu einem zugelassenen Arzneimittel.<\/p>","protected":false},"excerpt":{"rendered":"

    Bremelanotid hat eine echte FDA-zugelassene Erfolgsbilanz als Fertigarzneimittel, sein Anwendungsbereich ist jedoch begrenzt. Die RECONNECT-Studien untersuchten pr\u00e4menopausale Frauen mit erworbenem, generalisiertem HSDD \u2013 nicht M\u00e4nner, Leistungssteigerung oder ein generisches PT-141-Forschungsmaterial.<\/p>","protected":false},"author":1,"featured_media":739,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"358","pim_article_type":"Published evidence review","pim_evidence_level":"Two randomized phase 3 trials plus current FDA-approved prescribing information","pim_reviewer":"Site evidence editorial team","pim_reviewed_date":"2026-09-02","pim_editorial_note":"Source-checked on 2026-09-02. Null results, study size, model\/population limits and relevant conflicts are retained. This is not medical advice, a customer case or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"Primary\/regulatory sources, factual claims, numerical results, limitations and product-evidence boundary checked for batch 3.","pim_creation_method":"The editorial workflow began with linked PubMed primary papers, systematic reviews, PubChem identity records and FDA\/DailyMed regulatory records. Population or model, denominators, endpoints, numerical results, null findings, limitations and conflicts were extracted before drafting. AI-assisted drafting and original image generation were used; the final facts and evidence boundaries were checked against the linked records on 2026-09-02. This is not independent peer review.","pim_sources":"[{\"title\":\"RECONNECT bremelanotide phase 3 trials\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31599840\/\",\"note\":\"Primary phase 3 publication; PMID 31599840.\"},{\"title\":\"DailyMed Vyleesi prescribing information\",\"url\":\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf\",\"note\":\"Current FDA-approved finished-drug label.\"},{\"title\":\"PubChem Bremelanotide record\",\"url\":\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Bremelanotide\",\"note\":\"Free-base peptide identity; CID 9941379.\"}]","footnotes":""},"categories":[19],"tags":[],"class_list":["post-755","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-published-study-cases"],"yoast_head":"\nBremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope<\/title>\n<meta name=\"description\" content=\"Bremelanotide has a real FDA-approved finished-drug record, but its scope is narrow. The RECONNECT trials studied premenopausal women with acquired, genera\u2026\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/de\/phase-3-studien-zu-bremelanotid-reconnect-und-fda-zulassungshinweise\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope\" \/>\n<meta property=\"og:description\" content=\"Bremelanotide has a real FDA-approved finished-drug record, but its scope is narrow. The RECONNECT trials studied premenopausal women with acquired, genera\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/de\/phase-3-studien-zu-bremelanotid-reconnect-und-fda-zulassungshinweise\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-01T16:45:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope\",\"datePublished\":\"2026-09-01T16:45:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/\"},\"wordCount\":301,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-phase3-evidence.webp\",\"articleSection\":[\"Published Study Reviews\"],\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/\",\"name\":\"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-phase3-evidence.webp\",\"datePublished\":\"2026-09-01T16:45:45+00:00\",\"description\":\"Bremelanotide has a real FDA-approved finished-drug record, but its scope is narrow. The RECONNECT trials studied premenopausal women with acquired, genera\u2026\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-phase3-evidence.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/bremelanotide-phase3-evidence.webp\",\"width\":1672,\"height\":941,\"caption\":\"AI-generated illustration: Regulatory and two-trial evidence visualization for bremelanotide\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/bremelanotide-reconnect-phase-3-trials-and-fda-label\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/de\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bremelanotid RECONNECT-Studien: Endpunkte, Sicherheit und FDA-Umfang","description":"Bremelanotid hat eine echte FDA-zugelassene Erfolgsbilanz als Fertigarzneimittel, sein Anwendungsbereich ist jedoch begrenzt. Die RECONNECT-Studien untersuchten pr\u00e4menopausale Frauen mit erworbenen, generischen\u2026","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/de\/phase-3-studien-zu-bremelanotid-reconnect-und-fda-zulassungshinweise\/","og_locale":"de_DE","og_type":"article","og_title":"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope","og_description":"Bremelanotide has a real FDA-approved finished-drug record, but its scope is narrow. The RECONNECT trials studied premenopausal women with acquired, genera\u2026","og_url":"https:\/\/nhdbio.com\/de\/phase-3-studien-zu-bremelanotid-reconnect-und-fda-zulassungshinweise\/","og_site_name":"NHD","article_published_time":"2026-09-01T16:45:45+00:00","og_image":[{"width":1672,"height":941,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Verfasst von":"NHD Technical Team","Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope","datePublished":"2026-09-01T16:45:45+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/"},"wordCount":301,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp","articleSection":["Published Study Reviews"],"inLanguage":"de","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/","url":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/","name":"Bremelanotid RECONNECT-Studien: Endpunkte, Sicherheit und FDA-Umfang","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp","datePublished":"2026-09-01T16:45:45+00:00","description":"Bremelanotid hat eine echte FDA-zugelassene Erfolgsbilanz als Fertigarzneimittel, sein Anwendungsbereich ist jedoch begrenzt. Die RECONNECT-Studien untersuchten pr\u00e4menopausale Frauen mit erworbenen, generischen\u2026","breadcrumb":{"@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/bremelanotide-phase3-evidence.webp","width":1672,"height":941,"caption":"AI-generated illustration: Regulatory and two-trial evidence visualization for bremelanotide"},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/bremelanotide-reconnect-phase-3-trials-and-fda-label\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Bremelanotide RECONNECT Trials: Endpoints, Safety and FDA Scope"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Peptidrohstoffe und individuelle Peptidsynthese","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"NHD Technisches Team","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"Das technische Team von NHD verwaltet Katalogdokumentationen und Beweiszusammenfassungen f\u00fcr Forschungszwecke. Rezensierte Artikel verweisen auf von Experten begutachtete Artikel, Studienregister und beh\u00f6rdliche Aufzeichnungen, behalten Nullergebnisse und Studieneinschr\u00e4nkungen bei und unterscheiden ver\u00f6ffentlichte Interventionen von Katalogmaterialien. F\u00fcr die Strukturierung kann AI-unterst\u00fctztes Zeichnen verwendet werden; Quellenverkn\u00fcpfungen und Beweisgrenzen bleiben sichtbar. Bei dieser Arbeit handelt es sich nicht um eine unabh\u00e4ngige Begutachtung oder medizinische Beratung.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/de\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/comments?post=755"}],"version-history":[{"count":0,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/posts\/755\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/media\/739"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/media?parent=755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/categories?post=755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/de\/wp-json\/wp\/v2\/tags?post=755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}